PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
30.52
Positive P/E while Medical - Pharmaceuticals median is negative at -0.39. Peter Lynch would investigate competitive advantages in a distressed Medical - Pharmaceuticals.
2.64
P/S less than half the Medical - Pharmaceuticals median of 6.35. Walter Schloss would verify if this discount reflects fixable issues. Check margins versus peers.
2.81
P/B exceeding 1.5x Medical - Pharmaceuticals median of 1.71. Jim Chanos would check for potential asset write-down risks.
64.30
Positive FCF while Medical - Pharmaceuticals median shows negative FCF. Peter Lynch would examine cash flow generation advantage.
64.30
P/OCF of 64.30 versus zero operating cash flow in Medical - Pharmaceuticals. Walter Schloss would verify operational quality.
2.81
Fair value ratio exceeding 1.5x Medical - Pharmaceuticals median of 1.75. Jim Chanos would check for valuation bubble risks.
0.82%
Positive earnings while Medical - Pharmaceuticals median shows losses. Peter Lynch would examine earnings quality advantage.
1.56%
Positive FCF while Medical - Pharmaceuticals median shows negative FCF. Peter Lynch would examine cash generation advantage.